Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, 010018, China.
J Mater Sci Mater Med. 2021 Jan 27;32(1):17. doi: 10.1007/s10856-020-06472-9.
Osteoporosis is the most common disease involving bone degeneration. As the age of the population increases, the prevalence of the disease is expected to rise. However, current treatment methods do not provide a desirable solution for the restoration of the function of degenerated bones in patients with osteoporosis. This led to emergence of controlled delivery systems to increase drug bioavailability and efficacy specifically at the bone regeneration. In this study, an epimedin A (EA) complex drug system was prepared by solution blending method. In vitro cell-based experiments showed that the EA complex drug could significantly promote the differentiation and proliferation of osteoblasts and increase the alkaline phosphatase activity, calcium nodule formation, and the expression of osteogenesis-related genes and proteins. In vivo experiments further demonstrated that this novel drugs remarkably enhanced bone regeneration. These results suggest that EA may be used for the treatment of osteoporosis.
骨质疏松症是最常见的骨骼退行性疾病。随着人口年龄的增长，预计该病的患病率将会上升。然而，目前的治疗方法并不能为骨质疏松症患者退行性骨骼的功能恢复提供理想的解决方案。这导致了控制释放系统的出现，旨在专门提高骨再生部位的药物生物利用度和疗效。在本研究中，通过溶液共混法制备了淫羊藿素（EA）复合药物系统。体外基于细胞的实验表明，EA 复合药物能显著促进成骨细胞的分化和增殖，增加碱性磷酸酶活性、钙结节形成以及成骨相关基因和蛋白的表达。体内实验进一步证实了这种新型药物能显著促进骨再生。这些结果表明，淫羊藿素可能可用于治疗骨质疏松症。
